IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hendrix et al.

Group No.:

Serial No.: 10/556,224

Examiner:

Filed: November 9, 2005

For: 6-Cyclylmethyl- and 6-Alkylmethyl-Substituted Pyrazolepyrimidines

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: September 25, 2006

Susan M. Pellegrino

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Date: September 25, 2006

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175 Telephone: (203) 812-649

Facsimile:

(203) 812-6450 (203) 812-6459 Attorney for Applicants

Reg. No. 48,972

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/556,224 **Supplemental** Filing Date INFORMATION DISCLOSURE First Named Inventor Hendrix, Martin et al. STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number Le A 36 520 Sheet

Examiner	Cite No.1	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
nitials*	No.'	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US-					
		US-					
		US-			,		
		US-					
**		US-					
		US-	-				
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		U\$-					
		US-		****			
		US-					
		US-					
•		US-					
		US-					
	t	US-					

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	,,		
	F4	WO 03/037899	05-08-2003	Pfizer Limited		
	F5	WO 02/068423	09-06-2002	Bayer Aktiengesellscha	ft	
	F6	WO 02/055082	07-18-2002	Vernalis Research Limi	ed	

Examiner			Date	
Signature			Considered	
		ſ		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.